Methylphenidate

Generic name: Pronounced as (meth'' il fen' i date)
Brand names
  • Adhansia XR®
  • Aptensio XR®
  • Concerta®
  • Cotempla® XR-ODT
  • Jornay PM®
  • Metadate® CD
  • Metadate® ER
  • Methylin®
  • Methylin® ER
  • Quillichew® ER
  • Quillivant® XR
  • Ritalin®
  • Ritalin® LA
  • Ritalin® SR
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 01/15/2022

Methylphenidate can be habit-forming. Do not take a larger dose, take it more often, take it for a longer time, or take it in a different way than prescribed by your doctor. If you take too much methylphenidate, you may find that the medication no longer controls your symptoms, you may feel a need to take large amounts of the medication, and you may experience unusual changes in your behavior. Tell your doctor if you drink or have ever drunk large amounts of alcohol, use or have ever used street drugs, or have overused prescription medications.

Do not stop taking methylphenidate without talking to your doctor, especially if you have overused the medication. Your doctor will probably decrease your dose gradually and monitor you carefully during this time. You may develop severe depression if you suddenly stop taking methylphenidate after overusing it. Your doctor may need to monitor you carefully after you stop taking methylphenidate, even if you have not overused the medication, because your symptoms may worsen when treatment is stopped.

Do not sell, give away, or let anyone else take your medication. Selling or giving away methylphenidate may harm others and is against the law. Store methylphenidate in a safe place so no one else can take it accidentally or on purpose. Keep track of how much medication is left so you will know if any is missing.

Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with methylphenidate and each time you get more medication. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer's website to obtain the Medication Guide.

Methylphenidate is used as part of a treatment program to control symptoms of attention deficit hyperactivity disorder (ADHD; more difficulty focusing, controlling actions, and remaining still or quiet than other people who are the same age) in adults and children. Methylphenidate (Methylin) is also used to treat narcolepsy (a sleep disorder that causes excessive daytime sleepiness and sudden attacks of sleep). Methylphenidate is in a class of medications called central nervous system (CNS) stimulants. It works by changing the amounts of certain natural substances in the brain.

Methylphenidate comes as an immediate-release tablet, a chewable tablet, a solution (liquid), a long-acting (extended-release) suspension (liquid), an intermediate-acting (extended-release) tablet, a long-acting (extended-release) capsule, a long-acting (extended-release) tablet, a long-acting (extended-release) chewable tablet, and a long-acting (extended-release) orally disintegrating tablet (tablet that dissolves quickly in the mouth). The long-acting tablet, orally disintegrating tablets, and capsules supply some medication right away and release the remaining amount as a steady dose of medication over a longer time. All of these forms of methylphenidate are taken by mouth. The regular tablets, chewable tablets (Methylin), and solution (Methylin) are usually taken two to three times a day by adults and twice a day by children, preferably 35 to 40 minutes before meals. Adults who are taking three doses should take the last dose before 6:00 pm, so that the medication will not cause difficulty in falling asleep or staying asleep. The intermediate-acting tablets are usually taken once or twice a day, in the morning and sometimes in the early afternoon 30 to 45 minutes before a meal. The long-acting capsule (Metadate CD) is usually taken once a day before breakfast; the long-acting tablet (Concerta), long-acting chewable tablet (Quillichew ER), long-acting suspension (Quillivant XR), and long-acting capsules (Aptensio XR, Ritalin LA) are usually taken once a day in the morning with or without food. The long-acting suspension (Quillivant XR) will begin to work sooner if it is taken with food. The long-acting orally disintegrating tablet (Cotempla XR-ODT) and the long-acting capsule (Adhansia XR) is usually taken once daily in the morning and should be taken consistently, either always with food or always without food. The long-acting capsule (Jornay PM) is usually taken once daily in the evening (between 6:30 pm and 9:30 pm),and should be taken consistently, at the same time every evening and either always with food or always without food.

Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take methylphenidate exactly as directed.

Do not try to push the extended-release orally disintegrating tablet (Cotempla XR-ODT) through the blister pack foil. Instead, use dry hands to peel back the foil packaging. Immediately take out the tablet and place it in your mouth. The tablet will quickly dissolve and can be swallowed with saliva; no water is needed to swallow the tablet.

You should thoroughly chew the immediate-release chewable tablets and then drink a full glass (at least 8 ounces [240 milliliters]) of water or other liquid. If you take the immediate-release chewable tablet without enough liquid, the tablet may swell and block your throat and may cause you to choke. If you have chest pain, vomiting, or trouble swallowing or breathing after taking the chewable tablet, you should call your doctor or get emergency medical treatment immediately.

Swallow the intermediate-acting and long-acting tablets and capsules whole; do not split, chew, or crush them. However, if you cannot swallow the long-acting capsules (Aptensio XR, Jornay PM, Metadate CD, Ritalin LA), you may carefully open the capsules and sprinkle the entire contents on a tablespoon of cool or room temperature applesauce, or for long-acting capsules (Adhansia XR), you may open the capsules and sprinkle the entire contents on a tablespoon of applesauce or yogurt. Swallow (without chewing) this mixture immediately after preparation (within 10 minutes if taking Adhansia XR) and then drink a glass of water to make sure you have swallowed all of the medicine. Do not store the mixture for future use.

If you are taking the long-acting chewable tablet (Quillichew ER) and your doctor has told you to take part of the tablet to get the correct amount of your dose, break the 20 mg or 30 mg long-acting chewable tablet carefully along the lines that have been scored into it. However, the 40 mg long-acting chewable tablet is not scored and cannot be divided or split.

If you are taking the long-acting suspension (Quillivant XR), follow these steps to measure the dose:

  1. Remove the bottle of medication and dosing dispenser from the box. Check to be sure that the bottle contains liquid medication. Call your pharmacist and do not use the medication if the bottle contains powder or if there is no dosing dispenser in the box.

  2. Shake the bottle up and down for at least 10 seconds to mix the medication evenly.

  3. Remove the bottle cap. Check that the bottle adapter has been inserted into top of the bottle.

  4. If the bottle adapter has not been inserted into the top of the bottle, insert it by placing the bottom of the adapter into the opening of the bottle and pressing down firmly on it with your thumb. Call your pharmacist if the box does not contain a bottle adapter. Do not remove the bottle adapter from the bottle once it is inserted.

  5. Insert the tip of the dosing dispenser into the bottle adapter and push the plunger all the way down.

  6. Turn the bottle upside down.

  7. Pull the plunger back to withdraw the amount of oral suspension prescribed by your doctor. If you are not sure how to correctly measure the dose your doctor has prescribed, ask your doctor or pharmacist.

  8. Remove the dosing dispenser and slowly squirt the oral suspension directly into your mouth or your child's mouth.

  9. Replace the cap on the bottle and close tightly.

  10. Clean the dosing dispenser after each use by placing it in the dishwasher or by rinsing with tap water.

Your doctor may start you on a low dose of methylphenidate and gradually increase your dose, not more often than once every week.

Your condition should improve during your treatment. Call your doctor if your symptoms worsen at any time during your treatment or do not improve after 1 month.

Your doctor may tell you to stop taking methylphenidate from time to time to see if the medication is still needed. Follow these directions carefully.

Some methylphenidate products may not be able to be substituted for another. Ask your pharmacist if you have any questions about the type of methylphenidate product your doctor has prescribed.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before taking methylphenidate,

  • tell your doctor and pharmacist if you are allergic to methylphenidate, to any other medications, aspirin (if taking Adhansia XR), tartrazine dye (a yellow dye in some processed foods and medications; if taking Adhansia XR), or any of the ingredients in the methylphenidate product you are taking. Ask your doctor or check the Medication Guide for a list of the ingredients.

  • tell your doctor if you are taking monoamine oxidase (MAO) inhibitors, including isocarboxazid (Marplan), linezolid (Zyvox), methylene blue, phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), and tranylcypromine (Parnate), or have stopped taking them during the past 14 days. Your doctor will probably tell you not to take methylphenidate until at least 14 days have passed since you last took an MAO inhibitor.

  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: anticoagulants ('blood thinners') such as warfarin (Coumadin, Jantoven); antidepressants such as clomipramine (Anafranil), desipramine (Norpramin), and imipramine (Tofranil); decongestants (cough and cold medications); medications for heartburn or ulcers such as esomeprazole (Nexium, in Vimovo), famotidine (Pepcid), omeprazole (Prilosec, in Zegerid), or pantoprazole (Protonix); medications for high blood pressure; medications for seizures such as phenobarbital, phenytoin (Dilantin, Phenytek), and primidone (Mysoline); methyldopa; selective serotonin reuptake inhibitors (SSRIs) such as citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac, Sarafem, in Symbyax, others), fluvoxamine (Luvox), paroxetine (Brisdelle, Paxil, Pexeva), and sertraline (Zoloft); sodium bicarbonate (Arm and Hammer Baking Soda, Soda Mint); and venlafaxine (Effexor). If you are taking Ritalin LA, also tell your doctor if you take antacids or medications for heartburn or ulcers. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • tell your doctor if you or anyone in your family has or has ever had Tourette's syndrome (a condition characterized by the need to perform repeated motions or to repeat sounds or words), facial or motor tics (repeated uncontrollable movements), or verbal tics (repetition of sounds or words that is hard to control). Also tell your doctor if you have glaucoma (increased pressure in the eye that may cause vision loss), an overactive thyroid gland, or feelings of anxiety, tension, or agitation. Your doctor will probably tell you not to take methylphenidate if you have any of these conditions.

  • tell your doctor if anyone in your family has or has ever had an irregular heartbeat or has died suddenly. Also tell your doctor if you have recently had a heart attack and if you have or have ever had a heart defect, high blood pressure, an irregular heartbeat, heart or blood vessel disease, hardening of the arteries, cardiomyopathy (thickening of the heart muscle), or other heart problems. Your doctor will probably tell you not to take methylphenidate if you have a heart condition or if there is a high risk that you may develop a heart condition.

  • tell your doctor if you or anyone in your family has or has ever had depression, bipolar disorder (mood that changes from depressed to abnormally excited), mania (frenzied, abnormally excited mood), or has thought about or attempted suicide. Also tell your doctor if you have or ever have had seizures, an abnormal electroencephalogram (EEG; a test that measures electrical activity in the brain), circulation problems in your fingers or toes, or mental illness. If you are taking the long-acting tablet (Concerta), tell your doctor if you have a narrowing or blockage of your digestive system.

  • tell your doctor if you are pregnant or plan to become pregnant. If you become pregnant while taking methylphenidate, call your doctor.

  • tell your doctor if you are breastfeeding or plan to breastfeed. If you are breastfeeding while taking methylphenidate your doctor may tell you to watch your baby closely for unusual agitation, difficulty sleeping, poor appetite, or weight loss.

  • talk to your doctor about the risks and benefits of taking methylphenidate if you are 65 years of age or older. Older adults should not usually take methylphenidate because it is not as safe as other medications that can be used to treat the same condition.

  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking methylphenidate.

  • be aware that you should not drink alcoholic beverages while taking the long-acting chewable tablet (Quillichew ER), the long-acting orally disintegrating tablet (Cotempla® XR-ODT), or the long-acting capsule (Adhansia XR or Jornay PM).

  • if you have phenylketonuria (PKU, an inherited condition in which a special diet must be followed to prevent damage to your brain that can cause severe intellectual disability), you should know that the immediate-release and long-acting chewable tablets contain aspartame that forms phenylalanine.

  • you should know that methylphenidate should be used as part of a total treatment program for ADHD, which may include counseling and special education. Make sure to follow all of your doctor's and/or therapist's instructions.

Take the missed dose as soon as you remember it. Talk to your doctor or pharmacist about how late in the day you should take a missed dose of your medication so that it will not cause difficulty in falling asleep or staying asleep. However, if it is almost time for your next scheduled dose, skip the missed dose and continue your regular dosing schedule. If you are taking the long-acting capsule (Jornay PM), take the missed dose as soon as you remember it that night. However, if it is already the next morning, skip the missed dose of the long-acting capsule (Jornay PM) and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

  • Methylphenidate may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • nervousness

    • irritability

    • difficulty falling asleep or staying asleep

    • dizziness

    • nausea

    • vomiting

    • loss of appetite

    • weight loss

    • stomach pain

    • diarrhea

    • heartburn

    • dry mouth

    • headache

    • muscle tightness

    • drowsiness

    • uncontrollable movement of a part of the body

    • restlessness

    • decreased sexual desire

    • heavy sweating

    • back pain

  • Some side effects can be serious. If you experience any of the following symptoms, call your doctor immediately or get emergency medical treatment:

    • fast, pounding, or irregular heartbeat

    • chest pain

    • shortness of breath

    • excessive tiredness

    • slow or difficult speech

    • fainting

    • weakness or numbness of an arm or leg

    • seizures

    • changes in vision or blurred vision

    • agitation

    • believing things that are not true

    • feeling unusually suspicious of others

    • hallucinating (seeing things or hearing voices that do not exist)

    • motor tics or verbal tics

    • depression

    • abnormally excited mood

    • mood changes

    • frequent, painful erections

    • erection that lasts longer than 4 hours

    • numbness, pain, or sensitivity to temperature in the fingers or toes

    • skin color change from pale to blue to red in the fingers or toes

    • unexplained wounds on the fingers or toes

    • fever

    • hives

    • rash

    • blistering or peeling skin

    • itching

    • swelling of the eyes, face, lips, mouth, tongue, or throat

    • hoarseness

    • difficulty breathing or swallowing

  • Methylphenidate may slow children's growth or weight gain. Your child's doctor will watch his or her growth carefully. Talk to your child's doctor if you have concerns about your child's growth or weight gain while he or she is taking this medication. Talk to your child's doctor about the risks of giving methylphenidate to your child.

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature, away from light and excess heat and moisture (not in the bathroom). Store methylphenidate in a safe place so that no one else can take it accidentally or on purpose. Keep track of how many tablets or capsules or how much liquid is left so you will know if any medication is missing.

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include the following:

  • vomiting

  • nausea

  • diarrhea

  • fainting, blurred vision, or dizziness

  • restlessness

  • abnormally rapid breathing

  • anxiety

  • agitation

  • uncontrollable shaking of a part of the body

  • muscle twitching

  • seizures

  • loss of consciousness

  • inappropriate happiness

  • confusion

  • hallucinating (seeing things or hearing voices that do not exist)

  • sweating

  • flushing

  • headache

  • fever

  • fast, pounding, or irregular heartbeat

  • widening of pupils (black circles in the middle of the eyes)

  • dry mouth or nose

  • muscle weakness, fatigue, or dark urine

If you are taking methylphenidate long-acting tablets (Concerta), you may notice something that looks like a tablet in your stool. This is just the empty tablet shell, and this does not mean that you did not get your complete dose of medication.

Keep all appointments with your doctor and the laboratory. Your doctor may check your blood pressure and heart rate and order certain lab tests to check your response to methylphenidate.

This prescription is not refillable. Be sure to schedule appointments with your doctor on a regular basis so that you do not run out of medication.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

  • Methylphenidylacetate hydrochloride

Drug Interaction
Calcium Carbonate Calcium Carbonate Calcium carbonate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Candesartan Candesartan Methylphenidate may decrease the antihypertensive activities of Candesartan.
Cilostazol Cilostazol Methylphenidate may decrease the excretion rate of Cilostazol which could result in a higher serum level.
Estrogen and Progestin (Oral Contraceptives) Estrogen and Progestin (Oral Contraceptives) Conjugated estrogens may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Fenofibrate Fenofibrate Methylphenidate may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Guanfacine Guanfacine Methylphenidate may decrease the antihypertensive activities of Guanfacine.
Magnesium Hydroxide Magnesium Hydroxide Methylphenidate can cause an increase in the absorption of Magnesium hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.
Magnesium Oxide Magnesium Oxide Magnesium oxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Methylergonovine Methylergonovine The risk or severity of hypertension can be increased when Methylergometrine is combined with Methylphenidate.
Mycophenolate Mycophenolate Methylphenidate may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
Naratriptan Naratriptan The risk or severity of hypertension can be increased when Methylphenidate is combined with Naratriptan.
Olsalazine Olsalazine Olsalazine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Penbutolol Penbutolol Methylphenidate may decrease the antihypertensive activities of Acebutolol.
Potassium Potassium Potassium may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.
Prednisone Prednisone Methylphenidate may decrease the excretion rate of Prednisone which could result in a higher serum level.
Ranitidine Ranitidine The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Ranitidine.
Reserpine Reserpine Methylphenidate may decrease the antihypertensive activities of Reserpine.
Rizatriptan Rizatriptan Methylphenidate may decrease the excretion rate of Rizatriptan which could result in a higher serum level.
Sumatriptan Sumatriptan Methylphenidate may decrease the excretion rate of Sumatriptan which could result in a higher serum level.
Tacrolimus Tacrolimus Tacrolimus may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Tizanidine Tizanidine The therapeutic efficacy of Tizanidine can be decreased when used in combination with Methylphenidate.
Zolmitriptan Zolmitriptan The risk or severity of hypertension can be increased when Zolmitriptan is combined with Methylphenidate.
Ampicillin Injection Ampicillin Injection Ampicillin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Doxycycline Injection Doxycycline Injection Doxycycline may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Famotidine Injection Famotidine Injection The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Famotidine.
Fluconazole Injection Fluconazole Injection Fluconazole may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Foscarnet Injection Foscarnet Injection Foscarnet may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Hydromorphone Injection Hydromorphone Injection Hydromorphone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Levofloxacin Injection Levofloxacin Injection Methylphenidate may decrease the excretion rate of Levofloxacin which could result in a higher serum level.
Meperidine Injection Meperidine Injection Methylphenidate may decrease the excretion rate of Meperidine which could result in a higher serum level.
Metoclopramide Injection Metoclopramide Injection Methylphenidate may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Pamidronate Injection Pamidronate Injection Pamidronic acid may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Vancomycin Injection Vancomycin Injection Methylphenidate may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Altretamine Altretamine Amphetamine may increase the hypertensive activities of Methylphenidate.
Cefuroxime Cefuroxime Cefuroxime may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Cyclosporine Cyclosporine Cyclosporine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Torsemide Torsemide Methylphenidate may decrease the antihypertensive activities of Torasemide.
Olanzapine Olanzapine The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Olanzapine.
Entacapone Entacapone The risk or severity of adverse effects can be increased when Methylphenidate is combined with Entacapone.
Eprosartan Eprosartan Methylphenidate may decrease the antihypertensive activities of Eprosartan.
Meloxicam Meloxicam Meloxicam may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Oxcarbazepine Oxcarbazepine The therapeutic efficacy of Oxcarbazepine can be decreased when used in combination with Methylphenidate.
Pantoprazole Pantoprazole Pantoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Telmisartan Telmisartan Methylphenidate may decrease the antihypertensive activities of Telmisartan.
Temozolomide Temozolomide Methylphenidate may decrease the excretion rate of Temozolomide which could result in a higher serum level.
Zaleplon Zaleplon The therapeutic efficacy of Zaleplon can be decreased when used in combination with Methylphenidate.
Linezolid Linezolid Linezolid may increase the hypertensive activities of Methylphenidate.
Trimipramine Trimipramine The risk or severity of adverse effects can be increased when Methylphenidate is combined with Trimipramine.
Perindopril Perindopril Methylphenidate may decrease the antihypertensive activities of Perindopril.
Tenofovir Tenofovir Tenofovir may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Choline Magnesium Trisalicylate Choline Magnesium Trisalicylate Choline magnesium trisalicylate may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Dutasteride Dutasteride The risk or severity of hypertension can be increased when Methylphenidate is combined with Dutasteride.
Epinephrine Injection Epinephrine Injection The risk or severity of hypertension can be increased when Methylphenidate is combined with Epinephrine.
Eplerenone Eplerenone Methylphenidate may decrease the antihypertensive activities of Eplerenone.
Olmesartan Olmesartan Methylphenidate may decrease the antihypertensive activities of Olmesartan.
Zonisamide Zonisamide Methylphenidate may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Aripiprazole Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Methylphenidate.
Dexmethylphenidate Dexmethylphenidate The risk or severity of hypertension can be increased when Methylphenidate is combined with Dexmethylphenidate.
Atazanavir Atazanavir Atazanavir may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Almotriptan Almotriptan Methylphenidate may decrease the excretion rate of Almotriptan which could result in a higher serum level.
Eletriptan Eletriptan The risk or severity of hypertension can be increased when Eletriptan is combined with Methylphenidate.
Emtricitabine Emtricitabine Methylphenidate may decrease the excretion rate of Emtricitabine which could result in a higher serum level.
Memantine Memantine The risk or severity of adverse effects can be increased when Methylphenidate is combined with Memantine.
Tadalafil Tadalafil Methylphenidate may decrease the antihypertensive activities of Tadalafil.
Frovatriptan Frovatriptan The risk or severity of hypertension can be increased when Methylphenidate is combined with Frovatriptan.
Apomorphine Injection Apomorphine Injection The risk or severity of adverse effects can be increased when Methylphenidate is combined with Apomorphine.
Protriptyline Protriptyline The risk or severity of adverse effects can be increased when Methylphenidate is combined with Protriptyline.
Duloxetine Duloxetine Methylphenidate may decrease the excretion rate of Duloxetine which could result in a higher serum level.
Tinidazole Tinidazole Methylphenidate may decrease the excretion rate of Tinidazole which could result in a higher serum level.
Bosentan Bosentan Methylphenidate may decrease the antihypertensive activities of Bosentan.
Cefditoren Cefditoren Methylphenidate may decrease the excretion rate of Cefdinir which could result in a higher serum level.
Cyanocobalamin Injection Cyanocobalamin Injection Hydroxocobalamin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Eszopiclone Eszopiclone Eszopiclone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Ganciclovir Ganciclovir Methylphenidate may decrease the excretion rate of Ganciclovir which could result in a higher serum level.
Ribavirin Ribavirin Methylphenidate may decrease the excretion rate of Ribavirin which could result in a higher serum level.
Solifenacin Solifenacin The risk or severity of hypertension can be increased when Methylphenidate is combined with Solifenacin.
Valganciclovir Valganciclovir Methylphenidate may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Adefovir Adefovir Adefovir may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Dextroamphetamine Dextroamphetamine Amphetamine may increase the hypertensive activities of Methylphenidate.
Isocarboxazid Isocarboxazid Isocarboxazid may increase the hypertensive activities of Methylphenidate.
Ramelteon Ramelteon Methylphenidate may decrease the excretion rate of Ramelteon which could result in a higher serum level.
Fentanyl Fentanyl The risk or severity of hypertension can be increased when Methylphenidate is combined with Fentanyl.
Pregabalin Pregabalin The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Pregabalin.
Phenylephrine Phenylephrine The risk or severity of hypertension can be increased when Phenylephrine is combined with Methylphenidate.
Felbamate Felbamate The therapeutic efficacy of Felbamate can be decreased when used in combination with Methylphenidate.
Ranolazine Ranolazine Ranolazine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Rasagiline Rasagiline Rasagiline may increase the hypertensive activities of Methylphenidate.
Sitagliptin Sitagliptin Methylphenidate may decrease the excretion rate of Sitagliptin which could result in a higher serum level.
Varenicline Varenicline Methylphenidate may decrease the excretion rate of Varenicline which could result in a higher serum level.
Albuterol Albuterol Methylphenidate may decrease the excretion rate of Salbutamol which could result in a higher serum level.
Paliperidone Paliperidone The risk or severity of adverse effects can be increased when Paliperidone is combined with Methylphenidate.
Clofarabine Injection Clofarabine Injection Methylphenidate may decrease the excretion rate of Clofarabine which could result in a higher serum level.
Lubiprostone Lubiprostone Methylphenidate may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
Aliskiren Aliskiren Methylphenidate may decrease the antihypertensive activities of Aliskiren.
Pemetrexed Injection Pemetrexed Injection Methylphenidate may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Lisdexamfetamine Lisdexamfetamine The risk or severity of hypertension can be increased when Methylphenidate is combined with Lisdexamfetamine.
Sorafenib Sorafenib Sorafenib may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Levocetirizine Levocetirizine Methylphenidate may decrease the excretion rate of Levocetirizine which could result in a higher serum level.
Pegaptanib Injection Pegaptanib Injection Methylphenidate may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Azacitidine Injection Azacitidine Injection Methylphenidate may decrease the excretion rate of Azacitidine which could result in a higher serum level.
Lenalidomide Lenalidomide Methylphenidate may decrease the excretion rate of Lenalidomide which could result in a higher serum level.
Budesonide Budesonide Methylphenidate may decrease the excretion rate of Budesonide which could result in a higher serum level.
Desmopressin Desmopressin Desmopressin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Doripenem Injection Doripenem Injection Methylphenidate may decrease the excretion rate of Doripenem which could result in a higher serum level.
Arsenic Trioxide Injection Arsenic Trioxide Injection Methylphenidate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.
Desvenlafaxine Desvenlafaxine Methylphenidate may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.
Cevimeline Cevimeline Cevimeline may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Nebivolol Nebivolol Methylphenidate may decrease the antihypertensive activities of Nebivolol.
Certolizumab Injection Certolizumab Injection Methylphenidate may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.
Daptomycin Injection Daptomycin Injection Daptomycin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Methylnaltrexone Injection Methylnaltrexone Injection Methylphenidate may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Rufinamide Rufinamide The therapeutic efficacy of Rufinamide can be decreased when used in combination with Methylphenidate.
Midazolam Midazolam Methylphenidate may decrease the excretion rate of Midazolam which could result in a higher serum level.
Dexrazoxane Injection Dexrazoxane Injection Dexrazoxane may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Milnacipran Milnacipran Methylphenidate may decrease the excretion rate of Milnacipran which could result in a higher serum level.
Dexlansoprazole Dexlansoprazole Dexlansoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Plerixafor Injection Plerixafor Injection Methylphenidate may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Fesoterodine Fesoterodine Methylphenidate may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
Betaxolol Betaxolol Methylphenidate may decrease the antihypertensive activities of Betaxolol.
Iloperidone Iloperidone The risk or severity of adverse effects can be increased when Iloperidone is combined with Methylphenidate.
Prasugrel Prasugrel Methylphenidate may decrease the excretion rate of Prasugrel which could result in a higher serum level.
Lacosamide Lacosamide The therapeutic efficacy of Lacosamide can be decreased when used in combination with Methylphenidate.
Tolvaptan (low blood sodium) Tolvaptan (low blood sodium) Tolvaptan may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.
Dronedarone Dronedarone The risk or severity of hypertension can be increased when Methylphenidate is combined with Dronedarone.
Pralatrexate Injection Pralatrexate Injection Methylphenidate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Palonosetron Injection Palonosetron Injection Palonosetron may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Saxagliptin Saxagliptin Methylphenidate may decrease the excretion rate of Saxagliptin which could result in a higher serum level.
Telavancin Injection Telavancin Injection Methylphenidate may decrease the excretion rate of Telavancin which could result in a higher serum level.
Topotecan Topotecan Methylphenidate may decrease the excretion rate of Topotecan which could result in a higher serum level.
Asenapine Asenapine The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Asenapine.
Vigabatrin Vigabatrin The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Methylphenidate.
Dalfampridine Dalfampridine The risk or severity of seizure can be increased when Methylphenidate is combined with Dalfampridine.
Ceftaroline Injection Ceftaroline Injection Ceftaroline fosamil may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Lurasidone Lurasidone The risk or severity of adverse effects can be increased when Lurasidone is combined with Methylphenidate.
Acetaminophen Injection Acetaminophen Injection Acetaminophen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Vilazodone Vilazodone The risk or severity of hypertension can be increased when Methylphenidate is combined with Vilazodone.
Ipilimumab Injection Ipilimumab Injection Methylphenidate may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Denileukin Diftitox Injection Denileukin Diftitox Injection Aldesleukin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Terbutaline Injection Terbutaline Injection Methylphenidate may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Roflumilast Roflumilast Methylphenidate may decrease the excretion rate of Roflumilast which could result in a higher serum level.
Rivaroxaban Rivaroxaban Methylphenidate may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
Ruxolitinib Ruxolitinib Methylphenidate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Clobazam Clobazam The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Clobazam.
Deferiprone Deferiprone Methylphenidate may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Cabergoline Cabergoline The risk or severity of adverse effects can be increased when Methylphenidate is combined with Cabergoline.
Naloxone Injection Naloxone Injection Methylphenidate may decrease the excretion rate of Naloxone which could result in a higher serum level.
Ambrisentan Ambrisentan Methylphenidate may decrease the antihypertensive activities of Ambrisentan.
Fondaparinux Injection Fondaparinux Injection Methylphenidate may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
Ezogabine Ezogabine The therapeutic efficacy of Tiagabine can be decreased when used in combination with Methylphenidate.
Enzalutamide Enzalutamide Methylphenidate may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
Mirabegron Mirabegron Methylphenidate may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Teduglutide Injection Teduglutide Injection Methylphenidate may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Alogliptin Alogliptin Methylphenidate may decrease the excretion rate of Alogliptin which could result in a higher serum level.
Pomalidomide Pomalidomide Methylphenidate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Canagliflozin Canagliflozin Methylphenidate may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Methazolamide Methazolamide Methazolamide may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.
Trametinib Trametinib Methylphenidate may decrease the excretion rate of Trametinib which could result in a higher serum level.
Levomilnacipran Levomilnacipran Methylphenidate may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Ertapenem Injection Ertapenem Injection Ertapenem may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Vortioxetine Vortioxetine Methylphenidate may decrease the excretion rate of Vortioxetine which could result in a higher serum level.
Perampanel Perampanel The therapeutic efficacy of Perampanel can be decreased when used in combination with Methylphenidate.
Ketorolac Injection Ketorolac Injection Ketorolac may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Sofosbuvir Sofosbuvir Methylphenidate may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Dapagliflozin Dapagliflozin Dapagliflozin may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.
Apremilast Apremilast Methylphenidate may decrease the excretion rate of Apremilast which could result in a higher serum level.
Droxidopa Droxidopa Methylphenidate may decrease the excretion rate of Droxidopa which could result in a higher serum level.
Eslicarbazepine Eslicarbazepine The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Methylphenidate.
Testosterone Injection Testosterone Injection Methylphenidate may decrease the excretion rate of Testosterone which could result in a higher serum level.
Edoxaban Edoxaban Methylphenidate may decrease the excretion rate of Edoxaban which could result in a higher serum level.
Methamphetamine Methamphetamine Methylphenidate may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Tasimelteon Tasimelteon Methylphenidate may decrease the excretion rate of Tasimelteon which could result in a higher serum level.
Riociguat Riociguat Methylphenidate may decrease the antihypertensive activities of Riociguat.
Risperidone Injection Risperidone Injection The risk or severity of adverse effects can be increased when Risperidone is combined with Methylphenidate.
Haloperidol Injection Haloperidol Injection The risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenidate.
Amiloride Amiloride Amiloride may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.
Macitentan Macitentan Methylphenidate may decrease the antihypertensive activities of Macitentan.
Flibanserin Flibanserin The risk or severity of hypertension can be increased when Methylphenidate is combined with Flibanserin.
Brexpiprazole Brexpiprazole The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Methylphenidate.
Ziprasidone Injection Ziprasidone Injection The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methylphenidate.
Cariprazine Cariprazine The risk or severity of adverse effects can be increased when Cariprazine is combined with Methylphenidate.
Penicillin G Procaine Injection Penicillin G Procaine Injection Methylphenidate may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Ixazomib Ixazomib Methylphenidate may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Lesinurad Lesinurad Methylphenidate may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Amphotericin B Liposomal Injection Amphotericin B Liposomal Injection Amphotericin B may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Brivaracetam Injection Brivaracetam Injection The therapeutic efficacy of Brivaracetam can be decreased when used in combination with Methylphenidate.
Midodrine Midodrine The risk or severity of hypertension can be increased when Midodrine is combined with Methylphenidate.
Selexipag Selexipag Methylphenidate may decrease the antihypertensive activities of Selexipag.
Pimavanserin Pimavanserin The risk or severity of adverse effects can be increased when Methylphenidate is combined with Pimavanserin.
Furosemide Injection Furosemide Injection Methylphenidate may decrease the antihypertensive activities of Furosemide.
Lixisenatide Injection Lixisenatide Injection Methylphenidate may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
Doxepin (Insomnia) Doxepin (Insomnia) The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Doxepin.
Deutetrabenazine Deutetrabenazine Methylphenidate may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.
Valbenazine Valbenazine Methylphenidate may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Safinamide Safinamide Safinamide may increase the hypertensive activities of Methylphenidate.
Naldemedine Naldemedine Methylphenidate may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Benznidazole Benznidazole Methylphenidate may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Delafloxacin Delafloxacin Methylphenidate may decrease the excretion rate of Delafloxacin which could result in a higher serum level.
Ertugliflozin Ertugliflozin Ertugliflozin may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.
Apalutamide Apalutamide Methylphenidate may decrease the excretion rate of Apalutamide which could result in a higher serum level.
Baricitinib Baricitinib Methylphenidate may decrease the excretion rate of Baricitinib which could result in a higher serum level.
Sodium Zirconium Cyclosilicate Sodium Zirconium Cyclosilicate Sodium zirconium cyclosilicate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Lofexidine Lofexidine Methylphenidate may decrease the antihypertensive activities of Lofexidine.
Plazomicin Injection Plazomicin Injection Methylphenidate may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Cannabidiol Cannabidiol The therapeutic efficacy of Cannabidiol can be decreased when used in combination with Methylphenidate.
Stiripentol Stiripentol The therapeutic efficacy of Stiripentol can be decreased when used in combination with Methylphenidate.
Prucalopride Prucalopride Methylphenidate may decrease the excretion rate of Prucalopride which could result in a higher serum level.
Siponimod Siponimod The risk or severity of hypertension can be increased when Methylphenidate is combined with Siponimod.
Acyclovir Ophthalmic Acyclovir Ophthalmic Acyclovir may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Esomeprazole Injection Esomeprazole Injection Esomeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Brexanolone Injection Brexanolone Injection The therapeutic efficacy of Brexanolone can be decreased when used in combination with Methylphenidate.
Solriamfetol Solriamfetol The risk or severity of hypertension can be increased when Solriamfetol is combined with Methylphenidate.
Pitolisant Pitolisant Methylphenidate may decrease the excretion rate of Pitolisant which could result in a higher serum level.
Phenytoin Injection Phenytoin Injection The serum concentration of Phenytoin can be increased when it is combined with Methylphenidate.
Fosphenytoin Injection Fosphenytoin Injection The serum concentration of Fosphenytoin can be increased when it is combined with Methylphenidate.
Lumateperone Lumateperone The risk or severity of adverse effects can be increased when Lumateperone is combined with Methylphenidate.
Cenobamate Cenobamate The therapeutic efficacy of Cenobamate can be decreased when used in combination with Methylphenidate.
Selpercatinib Selpercatinib The risk or severity of hypertension can be increased when Methylphenidate is combined with Selpercatinib.
Opicapone Opicapone The risk or severity of adverse effects can be increased when Methylphenidate is combined with Opicapone.
Naxitamab-gqgk Injection Naxitamab-gqgk Injection The risk or severity of hypertension can be increased when Methylphenidate is combined with Naxitamab.
Progestin-Only (drospirenone) Oral Contraceptives Progestin-Only (drospirenone) Oral Contraceptives Drospirenone may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.
Viloxazine Viloxazine Methylphenidate may decrease the excretion rate of Viloxazine which could result in a higher serum level.
Tobramycin Injection Tobramycin Injection Tobramycin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Fenoprofen Fenoprofen Fenoprofen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Indomethacin Indomethacin Indomethacin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Mefenamic Acid Mefenamic Acid Mefenamic acid may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Naproxen Naproxen Naproxen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Tolmetin Tolmetin Tolmetin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Sulindac Sulindac Sulindac may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Trazodone Trazodone The risk or severity of hypertension can be increased when Methylphenidate is combined with Trazodone.
Isotretinoin Isotretinoin Methylphenidate may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
Sucralfate Sucralfate Sucralfate may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Sodium Bicarbonate Sodium Bicarbonate Sodium bicarbonate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Floxuridine Floxuridine Floxuridine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Phenobarbital Phenobarbital The serum concentration of Phenobarbital can be increased when it is combined with Methylphenidate.
Metaxalone Metaxalone Methylphenidate may decrease the excretion rate of Metaxalone which could result in a higher serum level.
Methotrexate Injection Methotrexate Injection Methotrexate may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Primidone Primidone The serum concentration of Primidone can be increased when it is combined with Methylphenidate.
Methsuximide Methsuximide The therapeutic efficacy of Methsuximide can be decreased when used in combination with Methylphenidate.
Diethylpropion Diethylpropion The risk or severity of hypertension can be increased when Methylphenidate is combined with Diethylpropion.
Chlorpromazine Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methylphenidate.
Diazepam Diazepam The therapeutic efficacy of Diazepam can be decreased when used in combination with Methylphenidate.
Oxazepam Oxazepam Methylphenidate may decrease the excretion rate of Oxazepam which could result in a higher serum level.
Flurazepam Flurazepam Methylphenidate may decrease the excretion rate of Flurazepam which could result in a higher serum level.
Clorazepate Clorazepate The therapeutic efficacy of Clorazepic acid can be decreased when used in combination with Methylphenidate.
Lorazepam Lorazepam The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Lorazepam.
Phenoxybenzamine Phenoxybenzamine Methylphenidate may decrease the antihypertensive activities of Phenoxybenzamine.
Carmustine Carmustine Carmustine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Amantadine Amantadine The risk or severity of adverse effects can be increased when Methylphenidate is combined with Amantadine.
Codeine Codeine Codeine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Bromocriptine Bromocriptine The risk or severity of adverse effects can be increased when Methylphenidate is combined with Bromocriptine.
Metaproterenol Metaproterenol The risk or severity of hypertension can be increased when Methylphenidate is combined with Orciprenaline.
Tranylcypromine Tranylcypromine Tranylcypromine may increase the hypertensive activities of Methylphenidate.
Phenelzine Phenelzine Phenelzine may increase the hypertensive activities of Methylphenidate.
Procarbazine Procarbazine Procarbazine may increase the hypertensive activities of Methylphenidate.
Ergoloid Mesylates Ergoloid Mesylates The risk or severity of hypertension can be increased when Methylphenidate is combined with Ergoloid mesylate.
Tetracycline Tetracycline Methylphenidate may decrease the excretion rate of Tetracycline which could result in a higher serum level.
Prochlorperazine Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenidate.
Thioridazine Thioridazine The risk or severity of adverse effects can be increased when Thioridazine is combined with Methylphenidate.
Trifluoperazine Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methylphenidate.
Bleomycin Bleomycin Bleomycin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Sulfadiazine Sulfadiazine Sulfadiazine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Methadone Methadone Methadone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Benztropine Benztropine The risk or severity of adverse effects can be increased when Methylphenidate is combined with Benzatropine.
Maprotiline Maprotiline Methylphenidate may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Ibuprofen Ibuprofen Ibuprofen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Trihexyphenidyl Trihexyphenidyl The risk or severity of adverse effects can be increased when Methylphenidate is combined with Trihexyphenidyl.
Orphenadrine Orphenadrine The risk or severity of adverse effects can be increased when Methylphenidate is combined with Orphenadrine.
Perphenazine Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Methylphenidate.
Azathioprine Azathioprine Methylphenidate may decrease the excretion rate of Azathioprine which could result in a higher serum level.
Fluphenazine Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Methylphenidate.
Phentermine Phentermine The risk or severity of hypertension can be increased when Phentermine is combined with Methylphenidate.
Amoxapine Amoxapine The risk or severity of adverse effects can be increased when Amoxapine is combined with Methylphenidate.
Sulfasalazine Sulfasalazine Sulfasalazine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Phenazopyridine Phenazopyridine Phenazopyridine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Carbamazepine Carbamazepine Methylphenidate may decrease the excretion rate of Carbamazepine which could result in a higher serum level.
Molindone Molindone The risk or severity of adverse effects can be increased when Molindone is combined with Methylphenidate.
Methyldopa Methyldopa Methylphenidate may decrease the antihypertensive activities of Methyldopa.
Clonidine Clonidine The risk or severity of adverse effects can be increased when Methylphenidate is combined with Clonidine.
Prazosin Prazosin Methylphenidate may decrease the antihypertensive activities of Prazosin.
Hydralazine Hydralazine Methylphenidate may decrease the antihypertensive activities of Hydralazine.
Cimetidine Cimetidine The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Cimetidine.
Gentamicin Injection Gentamicin Injection Gentamicin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Warfarin Warfarin The metabolism of Warfarin can be decreased when combined with Methylphenidate.
Clonazepam Clonazepam The therapeutic efficacy of Clonazepam can be decreased when used in combination with Methylphenidate.
Promethazine Promethazine The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Promethazine.
Meclofenamate Meclofenamate Meclofenamic acid may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Nitrofurantoin Nitrofurantoin Methylphenidate may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
Digoxin Digoxin Methylphenidate may decrease the excretion rate of Digoxin which could result in a higher serum level.
Loxapine Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Methylphenidate.
Chloroquine Chloroquine Methylphenidate may decrease the excretion rate of Chloroquine which could result in a higher serum level.
Ethosuximide Ethosuximide The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Methylphenidate.
Triamterene Triamterene Triamterene may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Chlorothiazide Chlorothiazide Methylphenidate may decrease the antihypertensive activities of Chlorothiazide.
Chlorthalidone Chlorthalidone Methylphenidate may decrease the antihypertensive activities of Chlorthalidone.
Metolazone Metolazone Methylphenidate may decrease the antihypertensive activities of Metolazone.
Isosorbide Isosorbide Isosorbide may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.
Secobarbital Secobarbital The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Secobarbital.
Desipramine Desipramine The risk or severity of adverse effects can be increased when Methylphenidate is combined with Desipramine.
Amitriptyline Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Methylphenidate.
Imipramine Imipramine The risk or severity of adverse effects can be increased when Methylphenidate is combined with Imipramine.
Probenecid Probenecid Methylphenidate may decrease the excretion rate of Probenecid which could result in a higher serum level.
Quinidine Quinidine Methylphenidate may decrease the excretion rate of Quinidine which could result in a higher serum level.
Procainamide Procainamide Methylphenidate may decrease the excretion rate of Procainamide which could result in a higher serum level.
Isoniazid Isoniazid Methylphenidate may decrease the excretion rate of Isoniazid which could result in a higher serum level.
Pyrazinamide Pyrazinamide Pyrazinamide may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Disopyramide Disopyramide Disopyramide may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Valproic Acid Valproic Acid The therapeutic efficacy of Valproic acid can be decreased when used in combination with Methylphenidate.
Butabarbital Butabarbital Butabarbital may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Liothyronine Liothyronine Liothyronine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Methimazole Methimazole Methylphenidate may decrease the excretion rate of Methimazole which could result in a higher serum level.
Chlorpropamide Chlorpropamide Methylphenidate may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.
Tolbutamide Tolbutamide Methylphenidate may decrease the excretion rate of Tolbutamide which could result in a higher serum level.
Tolazamide Tolazamide Methylphenidate may decrease the excretion rate of Tolazamide which could result in a higher serum level.
Baclofen Baclofen Baclofen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Ethambutol Ethambutol Ethambutol may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Methyclothiazide Methyclothiazide Methyclothiazide may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.
Hydrochlorothiazide Hydrochlorothiazide Methylphenidate may decrease the antihypertensive activities of Hydrochlorothiazide.
Chlorzoxazone Chlorzoxazone Chlorzoxazone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Pyridoxine Pyridoxine Pyridoxine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Folic Acid Folic Acid Folic acid may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Disulfiram Disulfiram The risk or severity of adverse effects can be increased when Disulfiram is combined with Methylphenidate.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) Methylphenidate may decrease the antihypertensive activities of Propranolol.
Minoxidil Minoxidil Methylphenidate may decrease the antihypertensive activities of Minoxidil.
Pseudoephedrine Pseudoephedrine The risk or severity of hypertension can be increased when Methylphenidate is combined with Pseudoephedrine.
Nortriptyline Nortriptyline The risk or severity of adverse effects can be increased when Methylphenidate is combined with Nortriptyline.
Spironolactone Spironolactone Spironolactone may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.
Amphotericin B Injection Amphotericin B Injection Amphotericin B may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Phytonadione Phytonadione Methylphenidate may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
Amikacin Injection Amikacin Injection Amikacin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Nadolol Nadolol Methylphenidate may decrease the antihypertensive activities of Nadolol.
Allopurinol Allopurinol Methylphenidate may decrease the excretion rate of Allopurinol which could result in a higher serum level.
Flavoxate Flavoxate Methylphenidate may decrease the excretion rate of Flavoxate which could result in a higher serum level.
Colchicine Colchicine Methylphenidate may decrease the excretion rate of Colchicine which could result in a higher serum level.
Cefaclor Cefaclor Cefaclor may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Cefadroxil Cefadroxil Cefadroxil may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Cefazolin Injection Cefazolin Injection Cefazolin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Cephalexin Cephalexin Cephalexin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Cefoxitin Injection Cefoxitin Injection Cefoxitin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Dacarbazine Dacarbazine Methylphenidate may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Acetazolamide Acetazolamide Acetazolamide may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.
Cefotaxime Injection Cefotaxime Injection Cefotaxime may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Calcitonin Salmon Injection Calcitonin Salmon Injection Salmon calcitonin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Pyrantel Pyrantel Methylphenidate may decrease the excretion rate of Pyrantel which could result in a higher serum level.
Captopril Captopril Methylphenidate may decrease the antihypertensive activities of Captopril.
Isoxsuprine Isoxsuprine The risk or severity of hypertension can be increased when Methylphenidate is combined with Isoxsuprine.
Ethacrynic Acid Ethacrynic Acid Etacrynic acid may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Colistimethate Injection Colistimethate Injection Colistimethate may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Metoprolol Metoprolol Methylphenidate may decrease the antihypertensive activities of Metoprolol.
Thiothixene Thiothixene The risk or severity of adverse effects can be increased when Thiothixene is combined with Methylphenidate.
Aspirin Aspirin Acetylsalicylic acid may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Salsalate Salsalate Salsalate may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Alprazolam Alprazolam Alprazolam may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Temazepam Temazepam Temazepam may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Triazolam Triazolam Methylphenidate may decrease the excretion rate of Triazolam which could result in a higher serum level.
Dicyclomine Dicyclomine Methylphenidate may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
Propantheline Propantheline Methylphenidate may decrease the excretion rate of Propantheline which could result in a higher serum level.
Trimethoprim Trimethoprim Methylphenidate may decrease the excretion rate of Trimethoprim which could result in a higher serum level.
Diltiazem Diltiazem Methylphenidate may decrease the antihypertensive activities of Diltiazem.
Nifedipine Nifedipine Methylphenidate may decrease the excretion rate of Nifedipine which could result in a higher serum level.
Timolol Timolol Methylphenidate may decrease the antihypertensive activities of Timolol.
Verapamil Verapamil Methylphenidate may decrease the excretion rate of Verapamil which could result in a higher serum level.
Atenolol Atenolol Methylphenidate may decrease the antihypertensive activities of Atenolol.
Pindolol Pindolol Methylphenidate may decrease the antihypertensive activities of Pindolol.
Cisplatin Injection Cisplatin Injection Methylphenidate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Diflunisal Diflunisal Diflunisal may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Piroxicam Piroxicam Piroxicam may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Bumetanide Bumetanide Methylphenidate may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.
Glipizide Glipizide Methylphenidate may decrease the excretion rate of Glipizide which could result in a higher serum level.
Indapamide Indapamide Methylphenidate may decrease the antihypertensive activities of Indapamide.
Amoxicillin Amoxicillin Methylphenidate may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Oxacillin Injection Oxacillin Injection Methylphenidate may decrease the excretion rate of Oxacillin which could result in a higher serum level.
Pentoxifylline Pentoxifylline Methylphenidate may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.
Pentamidine Injection Pentamidine Injection Pentamidine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Ceftriaxone Injection Ceftriaxone Injection Ceftriaxone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Labetalol Labetalol Methylphenidate may decrease the antihypertensive activities of Labetalol.
Auranofin Auranofin Methylphenidate may decrease the excretion rate of Auranofin which could result in a higher serum level.
Leuprolide Injection Leuprolide Injection Leuprolide may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Gemfibrozil Gemfibrozil Methylphenidate may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.
Guanabenz Guanabenz Methylphenidate may decrease the antihypertensive activities of Guanabenz.
Dipivefrin Ophthalmic Dipivefrin Ophthalmic Adefovir dipivoxil may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Ceftazidime Injection Ceftazidime Injection Ceftazidime may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Ketoprofen Ketoprofen Ketoprofen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Cefotetan Injection Cefotetan Injection Cefotetan may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Pimozide Pimozide The risk or severity of adverse effects can be increased when Pimozide is combined with Methylphenidate.
Enalapril Enalapril Methylphenidate may decrease the antihypertensive activities of Enalapril.
Flurbiprofen Flurbiprofen Flurbiprofen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Aztreonam Injection Aztreonam Injection Aztreonam may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Buspirone Buspirone Methylphenidate may decrease the excretion rate of Buspirone which could result in a higher serum level.
Ciprofloxacin Ciprofloxacin Methylphenidate may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.
Mesalamine Mesalamine Mesalazine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Diclofenac Diclofenac Diclofenac may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Nimodipine Nimodipine Methylphenidate may decrease the antihypertensive activities of Nimodipine.
Clozapine Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Methylphenidate.
Estazolam Estazolam The therapeutic efficacy of Estazolam can be decreased when used in combination with Methylphenidate.
Didanosine Didanosine Methylphenidate may decrease the excretion rate of Didanosine which could result in a higher serum level.
Pentostatin Injection Pentostatin Injection Methylphenidate may decrease the excretion rate of Pentostatin which could result in a higher serum level.
Benazepril Benazepril Methylphenidate may decrease the antihypertensive activities of Benazepril.
Etodolac Etodolac Etodolac may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Felodipine Felodipine Methylphenidate may decrease the antihypertensive activities of Felodipine.
Fosinopril Fosinopril Methylphenidate may decrease the antihypertensive activities of Fosinopril.
Nabumetone Nabumetone Nabumetone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Quinapril Quinapril Methylphenidate may decrease the antihypertensive activities of Quinapril.
Ramipril Ramipril Methylphenidate may decrease the antihypertensive activities of Ramipril.
Amlodipine Amlodipine Methylphenidate may decrease the antihypertensive activities of Amlodipine.
Lisinopril Lisinopril Methylphenidate may decrease the antihypertensive activities of Lisinopril.
Oxaprozin Oxaprozin Oxaprozin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Bisoprolol Bisoprolol Methylphenidate may decrease the antihypertensive activities of Bisoprolol.
Doxazosin Doxazosin Methylphenidate may decrease the antihypertensive activities of Doxazosin.
Terazosin Terazosin Methylphenidate may decrease the antihypertensive activities of Terazosin.
Isradipine Isradipine Methylphenidate may decrease the antihypertensive activities of Isradipine.
Omeprazole Omeprazole Omeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Gabapentin Gabapentin The therapeutic efficacy of Gabapentin can be decreased when used in combination with Methylphenidate.
Venlafaxine Venlafaxine Venlafaxine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Nizatidine Nizatidine The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Nizatidine.
Fluvoxamine Fluvoxamine Fluvoxamine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Nefazodone Nefazodone Methylphenidate may decrease the excretion rate of Nefazodone which could result in a higher serum level.
Lamotrigine Lamotrigine The therapeutic efficacy of Lamotrigine can be decreased when used in combination with Methylphenidate.
Losartan Losartan Methylphenidate may decrease the antihypertensive activities of Losartan.
Valacyclovir Valacyclovir Valaciclovir may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Tramadol Tramadol Tramadol may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Carboplatin Injection Carboplatin Injection Carboplatin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Moexipril Moexipril Methylphenidate may decrease the antihypertensive activities of Moexipril.
Lansoprazole Lansoprazole Lansoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Ifosfamide Injection Ifosfamide Injection Methylphenidate may decrease the excretion rate of Ifosfamide which could result in a higher serum level.
Nicardipine Nicardipine Methylphenidate may decrease the antihypertensive activities of Nicardipine.
Bupropion Bupropion The risk or severity of seizure can be increased when Methylphenidate is combined with Bupropion.
Ticlopidine Ticlopidine Ticlopidine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Metformin Metformin Metformin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Nisoldipine Nisoldipine Methylphenidate may decrease the antihypertensive activities of Nisoldipine.
Lamivudine Lamivudine Methylphenidate may decrease the excretion rate of Lamivudine which could result in a higher serum level.
Riluzole Riluzole The therapeutic efficacy of Riluzole can be decreased when used in combination with Methylphenidate.
Acarbose Acarbose Acarbose may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Gemcitabine Injection Gemcitabine Injection Methylphenidate may decrease the excretion rate of Gemcitabine which could result in a higher serum level.
Cidofovir Injection Cidofovir Injection Cidofovir may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Meropenem Injection Meropenem Injection Methylphenidate may decrease the excretion rate of Meropenem which could result in a higher serum level.
Clomipramine Clomipramine The risk or severity of adverse effects can be increased when Methylphenidate is combined with Clomipramine.
Fosfomycin Fosfomycin Methylphenidate may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
Mirtazapine Mirtazapine The risk or severity of hypertension can be increased when Mirtazapine is combined with Methylphenidate.
Trandolapril Trandolapril Methylphenidate may decrease the antihypertensive activities of Trandolapril.
Topiramate Topiramate The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Topiramate.
Valsartan Valsartan Methylphenidate may decrease the antihypertensive activities of Valsartan.
Pramipexole Pramipexole The risk or severity of adverse effects can be increased when Methylphenidate is combined with Pramipexole.
Carvedilol Carvedilol Methylphenidate may decrease the antihypertensive activities of Carvedilol.
Nilutamide Nilutamide Methylphenidate may decrease the excretion rate of Nilutamide which could result in a higher serum level.
Flutamide Flutamide Methylphenidate may decrease the excretion rate of Flutamide which could result in a higher serum level.
Selegiline Selegiline Selegiline may increase the hypertensive activities of Methylphenidate.
Propafenone Propafenone The risk or severity of hypertension can be increased when Methylphenidate is combined with Propafenone.
Irbesartan Irbesartan Methylphenidate may decrease the antihypertensive activities of Irbesartan.
Tamsulosin Tamsulosin Methylphenidate may decrease the excretion rate of Tamsulosin which could result in a higher serum level.
Ropinirole Ropinirole The risk or severity of adverse effects can be increased when Methylphenidate is combined with Ropinirole.
Finasteride Finasteride The risk or severity of hypertension can be increased when Methylphenidate is combined with Finasteride.
Quetiapine Quetiapine The risk or severity of adverse effects can be increased when Quetiapine is combined with Methylphenidate.
Cefepime Injection Cefepime Injection Cefepime may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Cefprozil Cefprozil Cefprozil may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Cefpodoxime Cefpodoxime Cefpodoxime may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Cetirizine Cetirizine Cetirizine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Tolcapone Tolcapone The risk or severity of adverse effects can be increased when Methylphenidate is combined with Tolcapone.
Capecitabine Capecitabine Methylphenidate may decrease the excretion rate of Capecitabine which could result in a higher serum level.
Abacavir Abacavir Methylphenidate may decrease the excretion rate of Abacavir which could result in a higher serum level.
Celecoxib Celecoxib Celecoxib may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Rosiglitazone Rosiglitazone Rosiglitazone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Tolterodine Tolterodine Methylphenidate may decrease the excretion rate of Tolterodine which could result in a higher serum level.
Oseltamivir Oseltamivir Oseltamivir may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Aluminum Hydroxide Aluminum Hydroxide Aluminum hydroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Balsalazide Balsalazide Balsalazide may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Nateglinide Nateglinide Methylphenidate may decrease the excretion rate of Nateglinide which could result in a higher serum level.
Levetiracetam Levetiracetam The therapeutic efficacy of Levetiracetam can be decreased when used in combination with Methylphenidate.
Rabeprazole Rabeprazole Methylphenidate can cause an increase in the absorption of Rabeprazole resulting in an increased serum concentration and potentially a worsening of adverse effects.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists